Insulin pump use in Europe

Diabetes Technology and Therapeutics

Volumn 12, Issue SUPPL. 1, 2010, Pages

  Renard, Eric ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN DERIVATIVE;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REVIEW;

BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; EUROPE; FRANCE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN INFUSION SYSTEMS; PATIENT EDUCATION AS TOPIC; UNITED STATES;

EID: 77956168420     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0189     Document Type: Review

References (18)

1. Pickup JC, Keen H, Parsons JA, Alberti KGMM: Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978;i:204-207.
2. Slama G, Hautecouverture M, Assan R, Tchobroutsky G: One to five days of continuous intravenous insulin infusion on seven diabetic patients. Diabetes 1974;23:732-738.
3. Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, Bringer J, Belicar P, Jeandidier N, Meyer L, Blin P, Augendre-Ferrante B, Tauber JP: Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998;21:977-982.
4. Renard E, Schaepelynck-Belicar P: Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab 2007;33:158-166.
5. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M: Improved glycemic control in poorly controlled patients with type 1 diabetes using realtime continuous glucose monitoring. Diabetes Care 2006; 29:2730-2732.
6. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M: Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the Real Trend study. Diabetes Care 2009;32:2245-2250.
7. Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27:1554-1558.
8. Renard E: Intensive insulin therapy today: 'basal-bolus' using multiple daily injections or CSII? Diabetes Metab 2005;31:4S40-4S44.
9. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F; European Society for Paediatric Endocrinology; Lawson Wilkins Pediatric Endocrine Society; International Society for Pediatric and Adolescent Diabetes; American Diabetes Association; European Association for the Study of Diabetes: Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paedia-tric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007;30:1653-1662.
10. Lassmann-Vague V, Clavel S, Guerci B, Hanaire H, Leroy R, Loeuille GA, Mantovani I, Pinget M, Renard E, Tubiana-Rufi N: When and how to treat a diabetic patient using an external insulin pump? Expert consensus. Societe francophone du diabete (ex ALFEDIAM) 2009. Diabetes Metab 2010; 36:79-85.
11. Guidance on the Use of Continuous Subcutaneous Insulin Infusion for Diabetes. Technology Appraisal Guidance No. 57. London: National Institute for Clinical Excellence, 2003.
12. Hammond P, Liebl A, Grunder S: International survey of insulin pump users: impact of continuous insulin infusion therapy on glucose control and quality of life. Prim Care Diabetes 2007;1:143-146.
13. Scuffham P, Carr L: The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003;20:586-593.
14. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ: Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabet Med 2005;22:1239-1245.
15. Radermecker RP, Scheen AJ: Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004;20:178-188.
16. Pickup JC, Harris A: Assessing quality of life for new diabetes treatments and technologies: a simple patient-centered score. J Diabetes Sci Technol 2007;1:394-399.
17. Colquitt J, Royle P, Waugh N: Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003;20:863-866.
18. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-1476.